Professor Stephen Riordan

Gastroenterology and the Liver

MBBS (Hons), MD (UNSW), FRACP, FRCP (London)

Scientific Publications

146. Interferon lambda 3 haplotype affects treatment response to interferon-alpha and ribavirin combination therapy in chronic hepatitis C. Nature Genetics 2009; 41: 1100-1104.
147. A phase 1b placebo-controlled, randomised study of the safety, pharmacokinetics and antiviral activity of p7 inhibitor BIT225 in patients with hepatitis C virus (HCV) infection. Procedings of HepDART Meeting, Hawaii 2009
148. An extended study of appendicectomy as a therapy for ulcerative proctitis. Proceedings of Digestive Diseases Week, New Orleans 2010.
149. Management of non-acetaminophen-induced acute liver failure. Nature Reviews Gastroenterology and Hepatology 2010; 7: 75-77.
150. Gut flora and hepatic encephalopathy in cirrhosis. New England Journal of Medicine 2010; 362;12: 1140-1142.
151. Development of occult hepatitis B in pregnancy: Implications for ante-natal screening in women from endemic areas. Obstetrics Medicine 2010; 3: 115-118.
152. Isolation and detection of Campylobacter concisus from saliva of healthy individuals and patients with inflammatory bowel disease. Journal of Clinical Microbiology 2010; 48: 2965-2967.
153. Gastroenterology and Hepatology. In: Harris P, Nagy S, Vardaxis N (Eds). Mosby’s Dictionary of Medical, Nursing & Health Professions, 2nd Australian and New Zealand Edition, Elsevier Australia, Sydney, 2010.
154. Hepatocellular carcinoma. In: Segal I, Pitchumoni CS, Sung J (Eds). Gastroenterology and Hepatology Without Frontiers: A Clinician’s Guide to a Global Phenomenon, Elsevier Australia, Sydney 2011.
155. Alcoholic liver disease. In: Segal I, Pitchumoni CS, Sung J (Eds). Gastroenterology and Hepatology Without Frontiers: A Clinician’s Guide to a Global Phenomenon, Elsevier Australia, Sydney 2011.
156. IL28B, HLA-C and KIR variants additively and interactively predict response to therapy in chronic hepatitis C virus infection. Public Library of Science Medicine 2011; In press.
157. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Medicine 2011, 3: 57.
158. Prevalence of Campylobacter species in adult Crohn’s disease and the preferential colonization sites of Campylobacter species in the human intestine. PLoS ONE / Public Library of Science 2011; 6(9): e25417.
159. Up-regulation of intestinal epithelial expression of TLR-4, MD-2, COX-2 and IL-8 by Campylobacter concisus: Possible relevance to the pathophysiology of inflammatory bowel disease. 2nd International Conference on Immune Tolerance, Amsterdam, October 2011
160. Angiotensin II receptor inhibition in multifocal inflammatory myofibroblastic tumour of the liver. Proceedings of Tow Research Awards, Sydney, October 2011.
161. Investigation of the enteric pathogenic potential of oral Campylobacter concisus strains isolated from patients with inflammatory bowel disease. PLoS ONE/ Public Library of Science 2012; 7: e38217.
162. Percutaneous angioplasty and stenting for mesenteric ischaemia. In: Forbes T (Ed). Angioplasty, Various Techniques and Challenges in Treatment of Congenital and Acquired Vascular Stenoses, In Tech, Rijeka, 2012: 1-8.
163. The effects of oral and enteric Campylobacter concisus strains on expression of TLR4, MD-2, TLR2, TLR5 and COX-2 in HT-29 cells. PLoS ONE/ Public Library of Science 2013; 8: e56888.
164. CCR5-32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. Genes & Immunity 2013; 14: 286-290.